Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects

Phase 1 Completed 36 enrolled Scynexis, Inc. Clinical Network Services (CNS) Pty Ltd · collab

RandomizedCrossoverOpen-labelOther

Summary

This is a Phase 1 open-label, randomized, two-period, crossover study to evaluate the effect of repeated oral doses of SCY-078 (Ibrexafungerp) on the pharmacokinetics of dabigatran administered orally to healthy subjects.

Timeline

Start: 2019-09-09
Primary completion: 2020-01-03
Completion: 2020-01-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dabigatran	Unknown	150 mg	Oral
Subject	Ibrexafungerp	Small molecule	750 mg	Oral

Indications

No indication recorded.